Skip to content
BiologicalX

Comparison

Bromantane vs Vitamin D3 + K2

Side-by-side of Bromantane and Vitamin D3 + K2. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.

Effects at a glance

Bromantane

  • Russian RCT base (Voznesenskaya 2010, n=728) supports 50 mg daily for asthenia and fatigue over 4 weeks
  • Atypical actogenic mechanism: induces tyrosine hydroxylase rather than direct monoamine release
  • Subjective profile is anxiolytic plus mildly motivating, distinct from classical stimulants
  • Long half-life of around 11 hours supports once-daily morning dosing
  • WADA-banned since 1996; relevant for tested athletes
  • Western evidence base is thin; most published trials are Russian-language and not independently replicated

Vitamin D3 + K2

  • Reduces non-vertebral fractures 10-20% in older adults at 800 IU/day or above when combined with calcium
  • VITAL trial showed neutral results on primary CV and cancer endpoints at 2000 IU/day over 5 years
  • Vitamin D supplementation reduces respiratory infection incidence ~10-20% in deficient populations
  • K2 MK-7 has 72-hour plasma half-life vs 1-2 hours for MK-4; once-daily dosing is sufficient
  • Synergy hypothesis is largely preclinical; dedicated combination RCTs are limited
  • Daily dosing outperforms bolus dosing for immune and infection outcomes

Side-by-side

Attribute Bromantane Vitamin D3 + K2
Category nootropic supplement
Also known as Ladasten, ADK-709, N-(4-bromophenyl)adamantan-2-amine cholecalciferol + menaquinone, D3/K2, vitamin D3 with MK-7
Half-life (hr) 11 360
Typical dose (mg) 75 0.05
Dosing frequency daily, morning daily with a fat-containing meal
Routes oral oral
Onset (hr) 3 24
Peak (hr) 168 168
Molecular weight 280.21 384.64
Molecular formula C16H20BrN C27H44O (D3); C46H64O2 (MK-7)
Mechanism Indirect dopaminergic and serotonergic actogenic activity via induction of tyrosine hydroxylase and selective increases in serotonin synthesis in hippocampus and hypothalamus. D3 converts to calcidiol then calcitriol, activating the vitamin D receptor (VDR) to increase intestinal calcium absorption and modulate immune and bone gene transcription. K2 carboxylates osteocalcin and matrix Gla protein, directing calcium toward bone and inhibiting vascular calcification.
Legal status Approved in Russia (Ladasten); unscheduled and unapproved in US, EU, UK Dietary supplement (global)
WADA status banned allowed
DEA / Rx Not scheduled in the US Not scheduled
Pregnancy Not recommended Recommended at standard doses for fetal bone development; consult clinician at higher doses
CAS 87913-26-6 67-97-0
PubChem CID 9576456 5280795
Wikidata Q4093816 Q139347

Safety profile

Bromantane

Common side effects

  • mild GI upset
  • headache
  • skin rash
  • occasional insomnia at higher doses

Contraindications

  • pregnancy
  • lactation
  • severe hepatic impairment
  • severe renal impairment
  • pediatric use

Interactions

  • MAOIs: theoretical additive dopaminergic and serotonergic activity(major)
  • levodopa and dopamine agonists: additive dopaminergic activity(moderate)
  • SSRIs and other serotonergic drugs: theoretical serotonergic additivity(moderate)
  • classical stimulants: theoretical additive activity, undocumented(moderate)

Vitamin D3 + K2

Common side effects

  • GI upset at high doses
  • headache (rare)
  • hypercalcemia (only at sustained very high D3 doses)

Contraindications

  • hypercalcemia
  • sarcoidosis
  • active hyperparathyroidism
  • warfarin therapy (K2 component requires stable intake)

Interactions

  • warfarin: K2 component can affect anticoagulation; maintain stable intake and inform anticoagulation clinic(moderate)
  • thiazide diuretics: additive calcium retention; hypercalcemia risk with high-dose D3(moderate)
  • digoxin and calcium channel blockers: additive effects from D3-induced hypercalcemia(moderate)
  • glucocorticoids: reduced vitamin D efficacy and bone effects(moderate)
  • cholestyramine and orlistat: bind fat-soluble vitamins; separate dosing by 2 to 4 hours(moderate)

Which Should You Take?

Vitamin D3 + K2 comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-A outcome catalogued. Bromantane is the right call when one of the conditionals below applies.

  • If your priority is focus or working memory, pick Bromantane.
  • If your priority is fatigue resistance, pick Bromantane.
  • If your priority is bone density, pick Vitamin D3 + K2.
  • If your priority is healthspan extension, pick Vitamin D3 + K2.

Edge case: If you want to avoid controlled substance, Vitamin D3 + K2 is the more accessible choice.

Default choice: Vitamin D3 + K2. Lower friction to source, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for Bromantane only if your priority sits squarely in the goals it owns above.

This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.

Common questions

What is the difference between Bromantane and Vitamin D3 + K2?

Bromantane and Vitamin D3 + K2 differ in category (nootropic vs supplement), mechanism, and typical dosing. See the side-by-side table for full details.

Which has a longer half-life, Bromantane or Vitamin D3 + K2?

Bromantane half-life is 11 hours; Vitamin D3 + K2 half-life is 360 hours.

Can you stack Bromantane with Vitamin D3 + K2?

Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.

Go deeper